Abstract:Background: There are emerging studies suggesting that non-alcoholic fatty liver disease (NAFLD) is a heterogeneous disease with multiple etiologies and molecular phenotypes. Fibrosis is the key process in NAFLD progression. In this study, we aimed to explore molecular phenotypes of NAFLD with a particular focus on the fibrosis phenotype and also aimed to explore the changes of macrophage subsets in the fibrosis subset of NAFLD. Methods: To assess the transcriptomic alterations of key factors in NAFLD and fibrosis progression, we included 14 different transcriptomic datasets of liver tissues. In addition, two single-cell RNA sequencing (scRNA-seq) datasets were included to construct transcriptomic signatures that could represent specific cells. To explore the molecular subsets of fibrosis in NAFLD based on the transcriptomic features, we used a high-quality RNA-sequencing (RNA-seq) dataset of liver tissues from patients with NAFLD. Non-negative matrix factorization (NMF) was used to analyze the molecular subsets of NAFLD based on the gene set variation analysis (GSVA) enrichment scores of key molecule features in liver tissues. Results: The key transcriptomic signatures on NAFLD including non-alcoholic steatohepatitis (NASH) signature, fibrosis signature, non-alcoholic fatty liver (NAFL) signature, liver aging signature and TGF-β signature were constructed by liver transcriptome datasets. We analyzed two liver scRNA-seq datasets and constructed cell type-specific transcriptomic signatures based on the genes that were highly expressed in each cell subset. We analyzed the molecular subsets of NAFLD by NMF and categorized four main subsets of NAFLD. Cluster 4 subset is mainly characterized by liver fibrosis. Patients with Cluster 4 subset have more advanced liver fibrosis than patients with other subsets, or may have a high risk of liver fibrosis progression. Furthermore, we identified two key monocyte-macrophage subsets which were both significantly correlated with the progression of liver fibrosis in NAFLD patients. Conclusion: Our study revealed the molecular subtypes of NAFLD by integrating key information from transcriptomic expression profiling and liver microenvironment, and identified a novel and distinct fibrosis subset of NAFLD. The fibrosis subset is significantly correlated with the profibrotic macrophages and M2 macrophage subset. These two liver macrophage subsets may be important players in the progression of liver fibrosis of NAFLD patients.

Spatial and Single‐Cell Transcriptomics Reveals the Regional Division of the Spatial Structure of MASH Fibrosis

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice

Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis

Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis

Microanatomy of the metabolic associated fatty liver disease (MAFLD) by single-cell transcriptomics

Single-cell Transcriptomics of Hepatic Stellate Cells Uncover Crucial Pathways and Key Regulators Involved in Non-Alcoholic Steatohepatitis

Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures

Integrated Single-Cell and Bulk RNA Sequencing Reveals Immune-Related SPP1+ Macrophages As a Potential Strategy for Predicting the Prognosis and Treatment of Liver Fibrosis and Hepatocellular Carcinoma

Single‐cell RNA sequencing reveals the heterogeneity and intercellular communication of hepatic stellate cells and macrophages during liver fibrosis

Spatial transcriptomics reveals the transcriptomic signatures in a mouse model of pediatric metabolic dysfunction-associated steatohepatitis

Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury

Characteristic Gene Expression in the Liver Monocyte-Macrophage-dc System is Associated with the Progression of Fibrosis in NASH.

Matrisome Gene-Based Subclassification of Patients with Liver Fibrosis Identifies Clinical and Molecular Heterogeneities.

Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice

Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages

Modeling Metabolic-Associated Steatohepatitis with Human Pluripotent Stem Cell-Derived Liver Organoids

Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH